Bouisset Frédéric, Ruidavets Jean-Bernard, Dallongeville Jean, Moitry Marie, Montaye Michele, Biasch Katia, Ferrières Jean
Department of Cardiology, Rangueil University Hospital, 31059 Toulouse, France.
Department of Epidemiology, INSERM UMR 1027, 31000 Toulouse, France.
J Clin Med. 2021 Jan 7;10(2):180. doi: 10.3390/jcm10020180.
Available data comparing long-term prognosis according to the type of acute coronary syndrome (ACS) are scarce, contradictory, and outdated. Our aim was to compare short- and long-term mortality in ST-elevated (STEMI) and non-ST-elevated myocardial infarction (non-STEMI) ACS patients.
Patients presenting with an inaugural ACS during the year 2006 and living in one of the three areas in France covered by the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) registry were included.
A total of 1822 patients with a first ACS-1121 (61.5%) STEMI and 701 (38.5%) non-STEMI-were included in the study. At the 28-day follow-up, the mortality rates were 6.7% and 4.7% ( = 0.09) for STEMI and non-STEMI patients, respectively, and after adjustment of potential confounding factors, the 28-day probability of death was significantly lower for non-STEMI ACS patients (Odds Ratio = 0.58 (0.36-0.94), = 0.03). At the 10-year follow-up, the death rates were 19.6% and 22.8% ( = 0.11) for STEMI and non-STEMI patients, respectively, and after adjustment of potential confounding factors, the 10-year probability of death did not significantly differ between non-STEMI and STEMI events (OR = 1.07 (0.83-1.38), = 0.59). Over the first year, the mortality rate was 7.2%; it then decreased and stabilized at 1.7% per year between the 2nd and 10th year following ACS.
STEMI patients have a worse vital prognosis than non-STEMI patients within 28 days following ACS. However, at the 10-year follow-up, STEMI and non-STEMI patients have a similar vital prognosis. From the 2nd year onwards following the occurrence of a first ACS, the patients become stable coronary artery disease patients with an annual mortality rate in the 2% range, regardless of the type of ACS they initially present with.
根据急性冠状动脉综合征(ACS)类型比较长期预后的现有数据稀缺、相互矛盾且过时。我们的目的是比较ST段抬高型心肌梗死(STEMI)和非ST段抬高型心肌梗死(非STEMI)ACS患者的短期和长期死亡率。
纳入2006年首次发生ACS且居住在法国心血管疾病趋势和决定因素监测(MONICA)注册中心覆盖的三个地区之一的患者。
本研究共纳入1822例首次发生ACS的患者,其中1121例(61.5%)为STEMI,701例(38.5%)为非STEMI。在28天随访时,STEMI和非STEMI患者的死亡率分别为6.7%和4.7%(P = 0.09),在调整潜在混杂因素后,非STEMI ACS患者28天死亡概率显著更低(比值比 = 0.58(0.36 - 0.94),P = 0.03)。在10年随访时,STEMI和非STEMI患者的死亡率分别为19.6%和22.8%(P = 0.11),在调整潜在混杂因素后,非STEMI和STEMI事件的10年死亡概率无显著差异(OR = 1.07(0.83 - 1.38),P = 0.59)。在第一年,死亡率为7.2%;随后下降并在ACS后的第2年至第10年稳定在每年1.7%。
在ACS后第28天内,STEMI患者的生命预后比非STEMI患者差。然而,在10年随访时,STEMI和非STEMI患者的生命预后相似。首次发生ACS后的第2年起,无论最初表现为何种类型的ACS,患者均成为稳定型冠状动脉疾病患者,年死亡率在2%左右。